Mini review: Prevention of mother–child transmission of HIV: 25 years of continuous progress toward the eradication of pediatric AIDS?

Blanche, Stéphane

doi:10.1080/21505594.2019.1697136

Cited by 9 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiretroviral treatment can prevent and control HIV transmission by suppressing the amount of virus in the blood plasma even without eliminating the virus from the body [5,6]. To maintain viral suppression, people living with HIV must take antiretroviral drugs for a long life through Highly active antiretroviral therapy (HAART).…”

Section: Introductionmentioning

confidence: 99%

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Adiningsih¹,

Widiyanti²,

Rokhmad³

2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

Tenofovir lamivudine efavirenz (TLE) as a single-tablet regimen is preferred to the long use of combination antiretroviral therapy. TLE is safer than another antiretroviral drug regimen for first-line of Human immunodeficiency virus (HIV) treatment. However, there is little information about the side effects of TLE during first-time therapy among people living with HIV in Jayapura. This study aimed to assess the TLE side effect and its efficacy among people living with HIV in Jayapura, Papua. This was a cross-sectional study involving 77 people living with HIV who took a single-tablet regimen of TLE for one to two years of antiretroviral therapy, comply the inclusion criteria, and provided consent to participate. Data collection was conducted through CD4 + tests, medical records, and interviews at Jayapura City Hospital. Descriptive statistics were used to determine the proportion of relevant variables. The results described that most groups of people living with HIV were adult group (93.5%), female (61.0%), Papuan (64.9%), had WHO clinical stage III-IV (67.5%), had CD4 + counts < 350 cell/µL in the early therapy (79.2%) and CD4 + counts ≥ 350 cell/µL at the time of the study (57.1%), and experienced TLE side effect (71.4%). The most symptoms of TLE side effects among people living with HIV were headache (61.8%), nausea (34.5%), and nightmare (29.1%). As many as 70.9% of people living with HIV experienced these symptoms for less than 2 weeks. TLE was still effective, indicated by an increase of CD4 + cell count average from 242.6 cell/mm 3 at the early therapy to 436.6 cell/mm 3 during this study, with good adherence to drug therapy (>95% adherence) by 53.2% of people living with HIV. The side effects of TLE can still be tolerated by most people living with HIV so the therapy can be continued without altering the regimen.

show abstract

Section: Introductionmentioning

confidence: 99%

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Adiningsih¹,

Widiyanti²,

Rokhmad³

2023

Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)

View full text Add to dashboard Cite

show abstract

“…1 New childhood infections mainly occur due to mother-to-child transmission (MTCT) during pregnancy, birthing, and breastfeeding. 2 Many infants may be exposed prenatally or postnatally, but do not acquire HIV due to the effective use of antiretroviral treatment (ART) in MTCT prevention programs. 2 Newborns, if not yet infected, can remain HIV and ART exposed with an unconfirmed HIV status until 18 months, or until post-cessation of breastfeeding.…”

mentioning

confidence: 99%

“…2 Many infants may be exposed prenatally or postnatally, but do not acquire HIV due to the effective use of antiretroviral treatment (ART) in MTCT prevention programs. 2 Newborns, if not yet infected, can remain HIV and ART exposed with an unconfirmed HIV status until 18 months, or until post-cessation of breastfeeding. 3 This infant population is termed HIV-exposed (HE) infants.…”

mentioning

confidence: 99%

Breastfeeding Outcomes and Associated Risks in HIV-Infected and HIV-Exposed Infants: A Systematic Review

Eccles

Toit

Jongh

et al. 2022

Breastfeeding Medicine

View full text Add to dashboard Cite

Purpose: To critically appraise recent literature regarding breastfeeding outcomes and associated risks in HIV-infected (HI) and HIV-exposed (HE) infants, using the AU2 c PRISMA-P statement guidelines. Materials and Methods: Five electronic databases were systematically searched to obtain English publications from the last 10 years (2010-2020), pertaining to breastfeeding outcomes and associated risks of HI and HE infants and children. Gray literature sources were also included. Data were extracted according to various data items and were synthesized using thematic synthesis. Results: Of the initial 7,151 sources identified, 42 articles were eligible for final inclusion. The final selection included 19 cohort studies and 2 expert committee reports, classified as gray literature. The remaining 21 studies comprised case-control, cross-sectional, and randomized controlled trial studies. The following themes were identified: breastfeeding outcomes in HI and HE infants, risks for suboptimal breastfeeding, HI and HE infant growth and developmental outcomes, and barriers and facilitators to feeding decisions. Most studies highlighted HE infants' growth and developmental outcomes and did not directly interrogate breastfeeding outcomes. The most prevalent risks for suboptimal breastfeeding were maternal factors affecting decision making for breastfeeding. Conclusions: This systematic review adds to the evidence of breastfeeding in HIV-affected mother-infant dyads. Findings reiterated that exclusive breastfeeding has a positive outcome on growth and development of all infants irrespective of HIV status. The review highlighted a dearth of research on breastfeeding outcomes of HI and HE infants. Large-scale prospective comparative studies should profile breastfeeding and developmental outcomes of infants with HIV infection or exposure and antiretroviral treatment exposure to enable early identification and intervention for this vulnerable population in low-income settings.

show abstract

“…We detail the epidemiological and clinical features of maternal-fetal listeriosis and present its pathophysiology [8,9,15,16]. Finally, Blanche reviews the stunning achievements that led to the control of congenital HIV, which started in the mid-nineties when zidovudine was proven effective in reducing vertical infection, and continues with the ongoing efforts in screening and organizing the care of pregnant women at a global scale [17].…”

mentioning

confidence: 99%

Maternal-fetal infections: Why do they matter?

Charlier

Lecuit

2020

Virulence

View full text Add to dashboard Cite

Mini review: Prevention of mother–child transmission of HIV: 25 years of continuous progress toward the eradication of pediatric AIDS?

Cited by 9 publications

References 45 publications

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Tenofovir Lamivudine Efavirenz Side Effect and Its Efficacy Among People Living with HIV in Jayapura

Breastfeeding Outcomes and Associated Risks in HIV-Infected and HIV-Exposed Infants: A Systematic Review

Maternal-fetal infections: Why do they matter?

Contact Info

Product

Resources

About